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cell carcinoma (RCC) grown on chicken embryo chorioallantoic membranes (CAM-PDX) as a model of early metastatic disease.
METHODS: Clinical grade MV-NIS was grown at Mayo Clinic facilities. Patient tumor cores were obtained from multiple independent sites of the primary tumor at the time of radical nephrectomy. Sectioned tumor fragments were implanted on chicken embryo chorioallantoic membranes and allowed to become vascularized over approximately seven days. In vivo infectivity studies were performed with measles virus expressing green fluorescent protein (MV-GFP), allowing real-time serial visualization of infection using fluorescent stereoscopy. Direct virus inoculation and intravascular administration were utilized. Volumetric Doppler US quantified xenograft vascularity as a measure of treatment response.
RESULTS: MV-GFP achieved robust infection of patientderived RCC tumors grown in the CAM model of early metastatic disease, as visualized by fluorescent stereoscopy. The kinetics and distribution of infection varied markedly between direct and intravenous administration, with direct inoculation achieving infection within 24 hours and resulting in near complete infection and xenograft destruction within four days. Intravenous administration achieved infection restricted by neovascularization of the xenograft with delayed kinetics and limited distribution compared to direct administration. Volumetric Doppler ultrasound quantified the vascularization index (percent xenograft volume composed of vasculature), correlating MV infection with decreased xenograft vascularity.
CONCLUSIONS: Our data show robust infection and destruction by oncolytic MV of patient-derived RCC xenografts grown in vivo on chicken embryo chorioallantoic membranes. Xenograft destruction was correlated with loss of vascularity as measured by volumetric Doppler ultrasound. Infection was more rapid and widespread after direct inoculation compared to intravenous administration. These data highlight the potential of oncolytic virotherapy as a therapeutic strategy against metastatic RCC. Importantly, the CAM-PDX model allows for rapid and high-throughput analysis of disease response to therapy by individual patient tumors, making in-vivo directed patient-specific treatment approaches a viable option for future oncolytic virotherapy trials. The objective of this study was to demonstrate creation of a patient derived xenograft (PDX) mouse model of RMC which could be subjected to treatment with anti-neoplastic agents.
METHODS: After institutional review board approval, severe combined immunodeficiency (SCID) mice (CB17/Icr-Prkdc/IcrIcoCrl, Charles River) were used to create PDX models. From the RMC tissue bank at our institution a patient sample was chosen for xenografts. Patient tumor samples were sliced and implanted in the SCID mouse flank under anesthesia. Short tandem repeat (STR) fingerprinting was used to confirm matching between the human and PDX tissue. The PDX mice were then exposed to various treatment agents (Table 1) . Tumors were measured weekly. Treatment continued until a measureable response was noted or tumor growth exceeded the protocol limits.
RESULTS: Two experiments of tumor implantation and treatment were completed. Each included three treatment arms and a control arm divided with equal numbers of PDX mice (N¼25 experiment 1, N¼42 experiment 2). Gemcitabine/Cisplatin dosing was reduced by one half during the first experiment due to intolerability. The remaining dosages were unchanged. After a mean treatment duration of 34.5 days, tumor shrinkage from baseline was only observed in the gemcitabine/cisplatin group, including 1/5 (20%) in experiment 1 and 3/6 (50%) in experiment 2 (figure 1) demonstrating a complete response. The other treatment arms showed a response compared to control, but maintained an increase in size from baseline CONCLUSIONS: We demonstrate the successful creation of a mouse RMC model with gemcitabine/cisplatin therapy showing excellent treatment efficacy. Further work will include result validation as well as genomic sequencing to detect predictive markers and establish novel therapeutics. INTRODUCTION AND OBJECTIVES: Sarcopenia is associated with poor prognosis, while high body mass index (BMI) is associated paradoxically with improved outcomes among clear cell renal cell carcinoma (ccRCC) patients. We examined how sarcopenia was associated with molecular subtypes of ccRCC and whether the association differed by BMI.
Source of
METHODS: The cohort consisted of 76 ccRCC patients treated by nephrectomy at Memorial Sloan Kettering Cancer Center who were transcriptomically-profiled. Computed tomography scans without contrast performed within 60-days of surgery were reviewed to determine skeletal muscle cross-sectional area. Sarcopenia (yes/no) was defined according to gender-specific international consensus definitions (skeletal muscle index of < 55cm2/m2 for men and <39 cm2/m2 for women). Obesity (yes/no) was defined as pre-surgical BMI 30 kg/m2. The ClearCode34 gene expression classifier categorized patients into e958 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 either ccA (less aggressive) or ccB (more aggressive) molecular subtypes. Age-and sex-adjusted logistic regression models estimated associations between sarcopenia and molecular subtype separately for obese and non-obese patients. Statistical significance was regarded as a p-value of<0.05. RESULTS: The cohort was predominantly male (77%), white (97%), and had localized disease (62%). Median age was 58.7 years (IQR: 34-86.7). Overall, 53% of patients were obese, 39% were sarcopenic, and 58% of tumors were ccB subtype. Sarcopenic patients were more likely to have ccB tumors (66.7%) compared to patients without sarcopenia (26.1%) p¼0.00008. Among patients who were not obese, aggressive ccB subtype was more common in sarcopenic (69.6%) than non-sarcopenic patients (30.8%) (p¼0.03). A similar pattern was observed among patients who were obese; aggressive ccB subtype was more common in sarcopenic (57.1%) than non-sarcopenic patients (24.2%) (p¼0.04).
CONCLUSIONS: While preliminary, our findings suggest that sarcopenia is associated with aggressive ccRCC regardless of obesity and lend biologic support to the observation that sarcopenia is associated with poor prognosis. It is not clear whether sarcopenia is a cause or consequence of tumor aggressiveness. RNA-Seq analysis of tumor tissue is being carried out to explore specific mechanisms underlying these observations. METHODS: In this IRB-approved retrospective study, 29 patients (15 aggressive and 14 non-aggressive) with pathologically confirmed ccRCC and a pre-operative multiphase CECT were identified. An abdominal radiologist supervised the segmentation of each tumor from a clinical, standard of care CT study on a dedicated workstation. We evaluated 6 different types of texture extraction techniques from every phase of the imaging study. Genome-wide DNAm profiles were generated from tumor tissue extracted from the same patients using the Infinium Methylation EPIC array. We correlated all 1495 radiomic features processed with 97 DNAm features selected based on their strength of separating non-aggressive from aggressive renal tumors and non-aggressive from normal kidney in 281 ccRCC from the Cancer Genome Atlas. We computed Pearson and Spearman correlations depending on data distribution, for all possible pairs of radiomics and DNAm features. The results were summarized within each of the 6 radiomics categories by the percent of correlation coefficients attaining nominal p<0.05 for each DNAm feature (suggestive of a positive signal) and presented in a heatmap (Figure 1) .
Source of Funding: Chanel grant (HF) and SOAR grant (HF & AJD) and Ruth L. Kirschstein Research Service Award T32CA082088 (AS).

MP72-18 ASSOCIATION OF COMPUTED TOMOGRAPHY-BASED RADIOMIC FEATURES WITH EPIGENETIC VARIATION OF CLEAR CELL
RESULTS: There were significant (p<0.05) correlations between the selected epigenetic features and the radiomics features. Gray-level difference method (GLDM) 2D and 3D were shown having a strong signal in the correlation with cg12697139 and cg16973527. In general, second-order statistical texture method: GLDM was seen to have the most correlation with selected epigenetic nodes.
CONCLUSIONS: To our knowledge, this is the first study to correlate epigenomic profiles with CECT based radiomics features of renal masses. We plan to validate the finding in a larger patient cohort study. (Gatto et al, Cell Reports, 2016) . However, it is unknown if GAG scores can detect RCC in earlier stages or non-ccRCC histologies.
METHODS: In this retrospective study, pre-operative plasma GAG levels from 162 RCC patients were compared to 19 healthy controls between 5/2011-2/2014. GAG scores were generated using 19 pre-specified properties and measured using capillary electrophoresis with laser induced fluorescence. GAG profile differences in RCC versus healthy controls were assessed using unsupervised clustering methods. A discovery set of 68 RCC vs. 19 healthy samples were first analyzed to update the historical GAG score. The new GAG score accuracy in RCC detection versus healthy subjects was validated using the remaining 94 RCC samples. RESULTS: Median age was similar between RCC and healthy cohorts, 60 years (IQR: 52-67) vs. 55 years (IQR: 50-60), respectively. In the RCC cohort, 113 (70%) were ccRCC and 49 (30%) non-ccRCC. RCC stage included 86 (53%) pT1, 66 (41%) pT2-3, and 12 (7%) pT4. GAG profiles in RCC clustered separately from healthy volunteers ( Figure 1A ). In the first discovery set (n¼68), the GAG score distinguished RCC from healthy subjects with an AUC equal to 0.999, 94.7% specificity and 100% sensitivity at an optimal cut-off equal to 0.87 ( Figure 1B ). In the validation set (n¼94), the GAG score achieved an AUC equal to 0.994 (95% CI: 0.985 -1) and 95.7% sensitivity ( Figure  1B) . GAG scores did not correlate with age or gender. GAG scores were elevated in all RCC samples compared to normal controls, irrespective and uncorrelated to stage, grade or histology.
CONCLUSIONS: Plasma GAG scores are measurably elevated in RCC compared to healthy individuals. It was possible to detect RCC irrespective of stage or histology with 95.7% sensitivity. GAG scores did not correlate with pathologic stage, grade, or histology. These findings suggest that GAG alterations occur early in tumor formation but are likely independent of progression. These findings warrant prospective validation to assess the clinical utility of pre-operative GAG scores as biomarkers for RCC. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e959
